Shengtai Pharmaceutical Schedules Fiscal Year 2010 First Quarter Financial Results and Conference Call
November 16 2009 - 6:00AM
PR Newswire (US)
WEIFANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai"
or "the Company"), a leading manufacturer and distributor of
high-quality, pharmaceutical grade glucose products in China, today
announced that it will issue financial results for the first
quarter fiscal year 2010 (three months ended September 30, 2009)
after the close of the stock market on Monday, November 16, 2009.
Management will conduct a conference call on Tuesday, November 17,
2009 at 8:00 A.M. Eastern Standard Time to discuss these results. A
question and answer session will follow management's presentation.
Ms. Yiru Melody Shi (CFO), and Ms. Shenglian Iris Wang (Investor
Relations Assistant Manager) will be the primary speakers on the
call. To participate, please call the following numbers ten minutes
before the call start time: Phone Number: + 1 (877) 407-8035 (North
America) Phone Number: + 1 (201) 689-8035 (International) A replay
of the call will be available through Tuesday, November 24, 2009,
at 11:59 P.M. Eastern Standard Time. For the replay, please call:
Phone Number: +1 (877) 660-6853 (North America) Phone Number: +1
(201) 612-7415 (International) Account Number: 286 Conference ID
Number: 337862 About Shengtai Pharmaceutical, Inc. Shengtai
Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai
Holding, Inc. (SHI), and the Chinese operating company of Weifang
Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and
supplier of pharmaceutical grade glucose used for medical purposes.
It also manufactures and supplies glucose and cornstarch products
to the food, beverage and industrial production industries in
China. For more information about Shengtai Pharmaceutical, Inc.,
please visit http://www.shengtaipharmaceutical.com/ . Forward
Looking Statements Certain statements in this press release and
oral statements made by the Company constitute forward-looking
statements concerning the Company's business and products. These
statements include, without limitation, statements regarding our
ability to prepare the Company for growth, the Company's planned
capacity expansion and predictions and guidance relating to the
Company's future financial performance. We have based these
forward- looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs, but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large- scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations. For
further information, please contact: Shengtai Pharmaceutical, Inc.
Ms. Yiru Melody Shi Chief Financial Officer Tel: +1-949-468-7078
Email: Ms. Shenglian Iris Wang Investor Relations Assistant Manager
Tel: +86-536-6295802 Email: DATASOURCE: Shengtai Pharmaceutical,
Inc. CONTACT: Shengtai Pharmaceutical, Inc., Ms. Yiru Melody Shi,
Chief Financial Officer, +1-949-468-7078, and Ms. Shenglian Iris
Wang, Investor Relations Assistant Manager, +86-536-6295802, Web
site: http://www.shengtaipharmaceutical.com/
Copyright